Notably, IRAK3 mRNA levels appear to be a biomarker of response to ICB therapy in patients with advanced or metastatic bladder cancers, because it is not associated to clinical outcome in a comparable patient subset from a TGCA cohort (15). Here, IRAK3 is linked to urinary bladder cancer.